This EFTR PE ratio history page last updated 7/11/2024
Period | Price | GAAP | TTM | PE |
Q1 2024 5/9/2024 | 2.14 | -2.16 | -13.08 | NA | Q4 2023 3/25/2024 | 13.76 | -3.42 | -16.92 | NA | Q3 2023 11/13/2023 | 13.95 | -3.25 | -19.00 | NA | Q2 2023 8/8/2023 | 18.60 | -4.25 | -21.50 | NA | Q1 2023 5/9/2023 | 13.13 | -6.00 | -21.50 | NA | Q4 2022 3/8/2023 | 12.55 | -5.50 | -13.75 | NA | Q3 2022 11/7/2022 | 12.25 | -5.75 | 2.75 | 4.5 | Q2 2022 8/9/2022 | 16.30 | -4.25 | 19.00 | 0.9 | Q1 2022 5/10/2022 | 60.00 | 1.75 | NA | NA | Q4 2021 3/16/2022 | 101.75 | 11.00 | NA | NA | Q3 2021 11/8/2021 | 278.00 | 10.50 | NA | NA |
|
Period | Price | GAAP | Annualized | PE |
Q1 2024 5/9/2024 | 2.14 | -2.16 | -8.64 | NA | Q4 2023 3/25/2024 | 13.76 | -3.42 | -13.68 | NA | Q3 2023 11/13/2023 | 13.95 | -3.25 | -13.00 | NA | Q2 2023 8/8/2023 | 18.60 | -4.25 | -17.00 | NA | Q1 2023 5/9/2023 | 13.13 | -6.00 | -24.00 | NA | Q4 2022 3/8/2023 | 12.55 | -5.50 | -22.00 | NA | Q3 2022 11/7/2022 | 12.25 | -5.75 | -23.00 | NA | Q2 2022 8/9/2022 | 16.30 | -4.25 | -17.00 | NA | Q1 2022 5/10/2022 | 60.00 | 1.75 | 7.00 | 8.6 | Q4 2021 3/16/2022 | 101.75 | 11.00 | 44.00 | 2.3 | Q3 2021 11/8/2021 | 278.00 | 10.50 | 42.00 | 6.6 |
|
On this page we presented the EFTR PE Ratio History information for eFFECTOR Therapeutics' stock.
The average EFTR PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 5.8. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average EFTR PE ratio history based on this TTM earnings result method is 2.7. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this EFTR PE ratio history result, against the recent PE: when this page was posted on 7/5/2024, the most recent closing price for EFTR had been 0.08, and the most recent quarterly earnings result, annualized, was 7. Meanwhile, the most recent TTM earnings summed to 2.75. From these numbers, we calculate the recent EFTR PE on 7/5/2024 based on annualized quarterly EPS was 0.0. Based on EFTR's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the historical average PE across our data set for eFFECTOR Therapeutics. Looking at the recent EFTR PE on 7/5/2024 based on TTM EPS, we calculate the ratio at 0.0. Based on EFTR's history, that recent PE is low relative to the historical average, with the recent PE 100.0% lower than the average PE across our eFFECTOR Therapeutics data set with TTM EPS used in the calculation at each period.
For self directed investors doing their due diligence on EFTR or any other given stock, valuation analysis for EFTR
can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can
help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios
justify the current stock market value.
That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate
eFFECTOR Therapeutics PE ratio history — or the PE history for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for
next earnings dates and also historical earnings surprises history for EFTR. Thanks for visiting, and the next
time you need to research EFTR PE Ratio History or the PE ratio history for another stock, we hope our site
will come to mind as your go-to PE ratio history research resource of choice.